Cytek BioSciences Inc (NASDAQ: CTKB) on Monday, soared 5.96% from the previous trading day, before settling in for the closing price of $6.21. Within the past 52 weeks, CTKB’s price has moved between $4.66 and $9.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 36.02%. The company achieved an average annual earnings per share of 34.24%. With a float of $116.78 million, this company’s outstanding shares have now reached $129.77 million.
Considering the fact that the conglomerate employs 676 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 54.92%, operating margin of -11.75%, and the pretax margin is -5.92%.
Cytek BioSciences Inc (CTKB) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Cytek BioSciences Inc is 9.34%, while institutional ownership is 58.03%. The most recent insider transaction that took place on Apr 19 ’24, was worth 117,400. In this transaction CHIEF TECHNOLOGY OFFICER of this company sold 20,000 shares at a rate of $5.87, taking the stock ownership to the 5,988,502 shares. Before that another transaction happened on Apr 09 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 1,900 for $7.00, making the entire transaction worth $13,304. This insider now owns 6,008,502 shares in total.
Cytek BioSciences Inc (CTKB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 34.24% per share during the next fiscal year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
Cytek BioSciences Inc (CTKB) is currently performing well based on its current performance indicators. A quick ratio of 5.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.04. Likewise, its price to free cash flow for the trailing twelve months is 28.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit 0.11 in the next quarter and is forecasted to reach 0.21 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
Compared to the last year’s volume of 0.69 million, its volume of 0.52 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 30.31%. Additionally, its Average True Range was 0.34.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 64.65%, which indicates a significant increase from 57.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.78% in the past 14 days, which was lower than the 76.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.93, while its 200-day Moving Average is $5.95. Nevertheless, the first resistance level for the watch stands at $6.71 in the near term. At $6.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.10. If the price goes on to break the first support level at $6.32, it is likely to go to the next support level at $6.06. Should the price break the second support level, the third support level stands at $5.93.
Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats
Market capitalization of the company is 813.51 million based on 128,811K outstanding shares. Right now, sales total 193,020 K and income totals -12,150 K. The company made 51,500 K in profit during its latest quarter, and 940 K in sales during its previous quarter.
